从“灰区”到靶点：HER2低表达乳腺癌的精准治疗破局之路

摘要

近年来，乳腺癌的发病率持续上升，推动了对人表皮生长因子受体2（HER2）靶向药物的深入研究。研究表明，新型抗体-药物偶联物（ADC）可能会对HER2低表达乳腺癌患者有益。然而，对于这种乳腺癌的临床病理特征、预后及与其他HER2阳性乳腺癌的差异，现有研究结果存在互相矛盾，缺乏一致性。目前，对于HER2低表达与乳腺癌患者预后的关系存在争议。深入研究HER2低表达乳腺癌将有助于进一步改善此类患者的临床结果。就HER2低表达乳腺癌相关的临床研究现状，最新治疗药物进展及临床预后进行综述。

关键词

乳腺肿瘤 / HER2低表达 / 临床病理特征 / 靶向治疗 / 综述

参考文献

[1] Kashyap D , Pal D , Sharma R , et al. Global increase in breast cancer incidence: risk factors and preventive measures[J]. Biomed Res Int, 2022, 2022: 9605439. DOI: 10.1155/2022/9605439.

[2] Corti C , Giugliano F , Nicolò E , et al. HER2—low breast cancer: a new subtype?[J]. Curr Treat Options Oncol, 2023, 24（5）: 468-478. DOI: 10.1007/s11864—023—01073—4.

[3] Tarantino P , Viale G , Press MF , et al. ESMO expert consensus statements （ECS） on the definition, diagnosis, and management of HER2—low breast cancer[J]. Ann Oncol, 2023, 34（8）: 645-659. DOI: 10.1016/j.annonc.2023.05.008.

[4] Cardoso F , Kyriakides S , Ohno S , et al. Early breast cancer: ESMO clinical practice guidelines for diagnosis, treatment and follow—up[J]. Ann Oncol, 2019, 30（8）: 1194-1220. DOI: 10.1093/annonc/mdz173.

[5] Nicolò E , Tarantino P , Curigliano G . Biology and treatment of HER2—low breast cancer[J]. Hematol Oncol Clin North Am, 2023, 37（1）: 117-132. DOI: 10.1016/j.hoc.2022.08.013.

[6] Franchet C , Djerroudi L , Maran—Gonzalez A , et al. 2021 update of the GEFPICS′ recommendations for HER2 status assessment in invasive breast cancer in France[J]. Ann Pathol, 2021, 41（6）: 507-520. DOI: 10.1016/j.annpat.2021.07.007.

[7] 孙正魁， 江泽飞 . 2022版《中国临床肿瘤学会乳腺癌诊疗指南》更新解读[J]. 中国肿瘤外科杂志， 2022， 14（3）： 212-218. DOI: 10.3969/j.issn.1674—4136.2022.03.003.

[8] 中国抗癌协会乳腺癌专业委员会 . 中国抗癌协会乳腺癌诊治指南与规范（2021版）[J]. 中国癌症杂志， 2021， 31（10）： 954-1040. DOI: 10.19401/j.cnki.1007—3639.2021.10.010.

[9] Tarantino P , Hamilton E , Tolaney SM , et al. HER2—low breast cancer: pathological and clinical landscape[J]. J Clin Oncol, 2020, 38（17）: 1951-1962. DOI: 10.1200/JCO.19.02488.

[10] Modi S , Park H , Murthy RK , et al. Antitumor activity and safety of trastuzumab deruxtecan in patients with HER2—low—expressing advanced breast cancer: results from a phase Ib study[J]. J Clin Oncol, 2020, 38（17）: 1887-1896. DOI: 10.1200/JCO.19.02318.

[11] Horisawa N , Adachi Y , Takatsuka D , et al. The frequency of low HER2 expression in breast cancer and a comparison of prognosis between patients with HER2—low and HER2—negative breast cancer by HR status[J]. Breast Cancer, 2022, 29（2）: 234-241. DOI: 10.1007/s12282—021—01301—5.

[12] Schettini F , Chic N , Brasó—Maristany F , et al. Clinical, pathological, and PAM50 gene expression features of HER2—low breast cancer[J]. NPJ Breast Cancer, 2021, 7（1）: 1. DOI: 10.1038/s41523—020—00208—2.

[13] Li KM , Wu SF , Sun MC , et al. Clinicopathological features of breast cancer with HER2 low expression: a real—world retrospective study[J]. Chin J Pathol, 2024, 53（7）: 691-696. DOI: 10.3760/cma.j.cn112151—20231108—00335.

[14] Zhang G , Ren C , Li C , et al. Distinct clinical and somatic mutational features of breast tumors with high—, low—, or non—expressing human epidermal growth factor receptor 2 status[J]. BMC Med, 2022, 20（1）: 142. DOI: 10.1186/s12916—022—02337—w.

[15] Zhang H , Katerji H , Turner BM , et al. HER2—low breast cancers: incidence, HER2 staining patterns, clinicopathologic features, MammaPrint and BluePrint genomic profiles[J]. Mod Pathol, 2022, 35（8）: 1075-1082. DOI: 10.1038/s41379—022—01056—0.

[16] Agostinetto E , Rediti M , Fimereli D , et al. HER2—low breast cancer: molecular characteristics and prognosis[J]. Cancers （Basel）, 2021, 13（11）: 2824. DOI: 10.3390/cancers13112824.

[17] Denkert C , Seither F , Schneeweiss A , et al. Clinical and molecular characteristics of HER2—low—positive breast cancer: pooled analysis of individual patient data from four prospective, neoadjuvant clinical trials[J]. Lancet Oncol, 2021, 22（8）: 1151-1161. DOI: 10.1016/S1470—2045（21）00301—6.

[18] Yang C , Zhang X , Chen Y , et al. Survival differences between HER2—0 and HER2—low—expressing breast cancer? A meta—analysis of early breast cancer patients[J]. Crit Rev Oncol Hematol, 2023, 185: 103962. DOI: 10.1016/j.critrevonc.2023.103962.

[19] 朱晓娟， 张虹， 张爽， 等 . 人表皮生长因子受体2低表达乳腺癌的临床病理学特征及预后[J]. 北京大学学报（医学版）， 2023， 55（2）： 243-250. DOI: 10.19723/j.issn.1671—167X.2023.02.008.

[20] 武鑫培， 罗银义， 王世明 . HER2低表达乳腺癌患者的临床病理特征及其预后分析[J]. 中国普外基础与临床杂志， 2023， 30（6）： 691-697. DOI: 10.7507/1007—9424.202211010.

[21] Fu Z , Li S , Han S , et al. Antibody drug conjugate: the “biological missile” for targeted cancer therapy[J]. Signal Transduct Target Ther, 2022, 7（1）: 93. DOI: 10.1038/s41392—022—00947—7.

[22] Eiger D , Agostinetto E , Saúde—Conde R , et al. The exciting new field of HER2—low breast cancer treatment[J]. Cancers (Basel), 2021, 13（5）: 1015. DOI: 10.3390/cancers13051015.

[23] Ogitani Y , Hagihara K , Oitate M , et al. Bystander killing effect of DS—8201a, a novel anti—human epidermal growth factor receptor 2 antibody—drug conjugate, in tumors with human epidermal growth factor receptor 2 heterogeneity[J]. Cancer Sci, 2016, 107（7）: 1039-1046. DOI: 10.1111/cas.12966.

[24] Hurvitz SA , Hegg R , Chung WP , et al. Trastuzumab deruxtecan versus trastuzumab emtansine in patients with HER2—positive metastatic breast cancer: updated results from DESTINY—Breast03, a randomised, open—label, phase 3 trial[J]. Lancet, 2023, 401（10371）: 105-117. DOI: 10.1016/S0140—6736（22）02420—5.

[25] Modi S , Jacot W , Yamashita T , et al. Trastuzumab deruxtecan in previously treated HER2—low advanced breast cancer[J]. N Engl J Med, 2022, 387（1）: 9-20. DOI: 10.1056/NEJMoa2203690.

[26] Gradishar WJ , Moran MS , Abraham J , et al. NCCN Guidelines ^® Insights: breast cancer, version 4.2023: featured updates to the NCCN guidelines [J]. J Natl Compr Canc Netw, 2023, 21（6）: 594-608. DOI: 10.6004/jnccn.2023.0031.

[27] Liu Z , Hu X , Li H , et al. Phase II study of SHR—A1811 in HER2—low breast cancer: Efficacy and safety[J]. Ann Oncol, 2023, 34（Suppl 2）: S123-S124. DOI: 10.1016/j.annonc.2023.09.1268.

[28] Heng J , Zhang Q , Yan M , et al. A phase I study of SHR—A1811 in metastatic HER2—low breast cancer[J]. J Clin Oncol, 2024, 42（16_suppl）: TPS1123. DOI: 10.1200/JCO.2024.42.16_suppl.TPS1123.

[29] Xu B , Wang J , Zhang Q , et al. RC48 in HER2—low metastatic breast cancer: Results from phase II C008 trial[J]. Clin Cancer Res, 2023, 29（12）: 2234-2242. DOI: 10.1158/1078—0432.CCR—22—2845.

[30] Zhang J , Ji D , Shen W , et al. MRG002 for HER2—low breast cancer: Phase I dose—escalation results[J]. Cancer Res Treat, 2024, 56（1）: 89-97. DOI: 10.4143/crt.2023.680.

[31] Fehrenbacher L , Cecchini RS , Geyer CE Jr , et al. NSABP B—47/NRG oncology phase III randomized trial comparing adjuvant chemotherapy with or without trastuzumab in high—risk invasive breast cancer negative for HER2 by FISH and with IHC 1+ or 2+[J]. J Clin Oncol, 2020, 38（5）: 444-453. DOI: 10.1200/JCO.19.01455.

[32] Geuijen CAW , De Nardis C , Maussang D , et al. Unbiased combinatorial screening identifies a bispecific IgG1 that potently inhibits HER3 signaling via HER2—guided ligand blockade[J]. Cancer Cell, 2021, 39（8）: 1163-1164. DOI: 10.1016/j.ccell.2021.06.013.

[33] Jäger M , Schoberth A , Ruf P , et al. The trifunctional antibody ertumaxomab destroys tumor cells that express low levels of human epidermal growth factor receptor 2[J]. Cancer Res, 2009, 69（10）: 4270-4276. DOI: 10.1158/0008—5472.CAN—08—2861.

[34] Chick RC , Clifton GT , Hale DF , et al. Subgroup analysis of nelipepimut—S plus GM—CSF combined with trastuzumab versus trastuzumab alone to prevent recurrences in patients with high—risk, HER2 low—expressing breast cancer[J]. Clin Immunol, 2021, 225: 108679. DOI: 10.1016/j.clim.2021.108679.

[35] Brown TA , Mittendorf EA , Hale DF , et al. Prospective, randomized, single—blinded, multi—center phase II trial of two HER2 peptide vaccines, GP2 and AE37, in breast cancer patients to prevent recurrence[J]. Breast Cancer Res Treat, 2020, 181（2）: 391-401. DOI: 10.1007/s10549—020—05638—x.

基金资助

国家自然科学基金(82072909)

2019年度江苏省第五期“333工程”科研项目资助计划(BRA2019182)

江苏省第十六批“六大人才高峰”高层次人才选拔培养资助计划(YY-217)